Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpectra (di/ S) Regulatory News (SPSC)

Share Price Information for Spectra (di/ S) (SPSC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 260.00
Bid: 220.00
Ask: 300.00
Change: 0.00 (0.00%)
Spread: 80.00 (36.364%)
Open: 260.00
High: 260.00
Low: 260.00
Prev. Close: 260.00
SPSC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

14 Feb 2012 07:00

RNS Number : 3407X
Spectra Systems Corporation
14 February 2012
 



For immediate release

14 February 2012

 

 

Spectra Systems Corporation

 

("Spectra" or the "Company")

Appointment of Non-Executive Director

Spectra, a leading provider of advanced technology solutions for banknote and product authentication, is pleased to announce that on 13 February 2012 Jeffrey Donohue joined the Company as a Non-Executive director, replacing Mark Curcio, whose resignation as a Non-Executive director was announced on 10 February 2012.

Jeffrey Peter Donohue (aged 40) is Corporate Counsel for Novartis Institutes for BioMedical Research, Inc. ("NIBRI"), the research arm of the global healthcare products company Novartis. Mr. Donohue provides legal guidance on NIBRI's strategic acquisitions, licensing agreements, academic and government-backed consortia, and drug discovery collaborations. Mr. Donohue also is an Adjunct Professor at Boston University School of Law, USA, where he teaches advanced courses on licensing and intellectual property transactions.

 

Before joining NIBRI, Mr. Donohue served as Corporate Counsel at Vertex Pharmaceuticals Incorporated, a pharmaceutical company based in Cambridge, Massachusetts, USA. Mr. Donohue started his legal career at Kirkpatrick & Lockhart LLP (now K&L Gates), where he spent seven years advising clients on corporate governance, mergers and acquisitions, and securities matters. Mr. Donohue obtained his Juris Doctor from Boston University and a B.A. from Brandeis University.

Mr. Donohue was also a director of Raise The Sky Inc., from March 2009 until August 2010. There is no further information that is required to be disclosed in relation to Mr. Donohue pursuant to Schedule 2(g) of the AIM Rules for Companies.

Commenting on the appointment, Dr. Nabil Lawandy, Chief Executive of Spectra, said: "Jeff is a timely addition to the Spectra Board of Directors as we explore potential acquisitions and implement the next phase of our growth strategy."

Enquiries:

 

Spectra Systems Corporation

Dr. Nabil Lawandy, Chief Executive Officer Tel: +1 (0) 401 274 4700

 

WH Ireland Limited

Chris Fielding (Head of Corporate Finance) Tel: +44 (0) 20 7220 1650

 

Media Enquires:

The Communications Portfolio Limited

Ariane Comstive / Caolan Mahon Tel: +44 (0) 20 7536 2028 / 2029

ariane.comstive@communications-portfolio.co.uk

 

- Ends -

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOASFFFWDFESEFE
Date   Source Headline
27th Mar 20247:00 amRNSAudited results for 12 months ended 31 Dec 2023
11th Jan 20247:00 amRNSExercise of Options and Director/PDMR Shareholding
28th Dec 20237:00 amRNSExercise of Options
21st Dec 202312:15 pmRNSCompletion of Acquisition
15th Dec 20234:35 pmRNSExercise of Options and transfer of shares
4th Dec 20237:00 amRNSAcquisition of Cartor Holdings Limited
6th Nov 20234:43 pmRNSTR-1
12th Oct 20237:00 amRNSLargest Central Bank Consumables Order
25th Sep 20237:00 amRNSInterim Results for Six Months Ended 30 June 2023
7th Jul 20236:01 pmRNSRemoval of Regulation S restrictions from shares
26th Jun 20233:22 pmRNSAnnual General Meeting Lack of Quorum
30th May 20237:00 amRNSAppointment of Chief Financial Officer
25th Apr 20237:00 amRNSAdditional Sensor Services Contract Amendment
24th Apr 20237:00 amRNSResignation of Chief Financial Officer
19th Apr 20237:05 amRNSRemoval of Reg S restrictions from common stock
6th Apr 20237:00 amRNSExercise of Options
31st Mar 20235:14 pmRNSRemoval of Reg S restrictions from shares
21st Mar 202311:44 amRNSDividend Record Date
20th Mar 20237:00 amRNSAudited results for year ended 31 December 2022
16th Mar 20234:35 pmRNSExercise of Options
6th Mar 202310:39 amRNSRemoval of Reg S restrictions from common stock
11th Oct 20226:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20227:00 amRNSContract Amendment to a Central Bank
21st Sep 20227:00 amRNSExercise of Options
12th Sep 20227:05 amRNSAppointment of Non-Executive Director
12th Sep 20227:00 amRNSInterim Results for Six Months Ended 30 June 2022
16th Aug 20227:00 amRNSFirst Banknote Disinfection System Sold
15th Aug 20227:00 amRNSNew Central Bank Contract Amendment
28th Jul 20227:00 amRNSShare Buy-Back
1st Jul 20222:31 pmRNSShare Buy-Back
28th Jun 20227:00 amRNSShare Buy-Back
15th Jun 20227:00 amRNSAdditional Central Bank Development Revenues
14th Jun 20227:00 amRNSAppointment of Chief Financial Officer
13th Jun 20227:00 amRNSAnnual General Meeting Update
25th May 20227:00 amRNSExercise of Options and Director/PDMR Shareholding
20th May 20228:44 amRNSRemoval of Regulation S restrictions from shares
20th May 20228:41 amRNSResignation of Chief Financial Officer
3rd May 20227:00 amRNSPosting of Annual Report & Notice of AGM
6th Apr 20221:36 pmRNSRemoval of Reg S restrictions from common stock
28th Mar 20227:00 amRNSGrant of Share Options
21st Mar 20227:00 amRNSResults twelve months ended 31 December 2021
24th Jan 20227:00 amRNSNew contract awards
21st Jan 20227:00 amRNSExercise of Options
6th Dec 20217:00 amRNSNew K-cup Orders in Q4 Exceed Expectations
2nd Nov 20213:37 pmRNSExercise of Options
25th Oct 20214:18 pmRNSRemoval of Regulation S restrictions
11th Oct 20217:00 amRNSLarge Central Bank Order
13th Sep 202110:27 amRNSHolding(s) in Company
25th Aug 202111:23 amRNSRemoval of Regulation S restrictions
21st Jul 20217:00 amRNSBanknote cleaning system also deactivates Covid-19

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.